Drug Profile
VGX 3200
Alternative Names: GHRH 1-44; GHRH-1-44-NH2; Growth Hormone-Releasing Factor 44; hpGRF 44; VGX-3200Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Baylor College of Medicine
- Developer Inovio Pharmaceuticals
- Class Gene therapies
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia; Cachexia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia in USA (IM, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cachexia in USA (IM, Injection)
- 30 Apr 2012 Preclinical development is ongoing in USA